Literature DB >> 30125561

Barbiturates enhance itch-associated scratching in atopic dermatitis mice: A possible clue to understanding nocturnal pruritus in atopic dermatitis.

Masanori Fujii1, Kaori Takeuchi2, Yuna Umehara2, Masafumi Takeuchi2, Takanori Nakayama2, Sayaka Ohgami2, Erika Asano2, Takeshi Nabe3, Susumu Ohya4.   

Abstract

In chronic pruritic diseases such as atopic dermatitis, pruritus is exacerbated during nocturnal sleep; however, the underlying mechanism remains unclear. We previously demonstrated that acute administration of the sedative-hypnotics ethanol markedly enhanced itch-associated spontaneous scratching in a diet-induced mouse model of atopic dermatitis. In the present study, to expand our previous finding and provide a general mechanism for the central modulation of chronic itch, we examined whether other hypnotic drugs, such as barbiturates and benzodiazepines, also enhance scratching, and further investigated the underlying mechanism. Barbiturates markedly enhanced spontaneous scratching in the atopic dermatitis model but not controls. However, unexpectedly, benzodiazepines only slightly increased scratching, and the selective γ-aminobutyric acid type A (GABAA) receptor agonist, muscimol, had no effect. Local injection studies have demonstrated that barbiturates act at the supraspinal level to enhance scratching. Barbiturate-induced scratching was inhibited not only by GABAA receptor antagonists but also by an L-type voltage-dependent calcium channel (L-VDCC) agonist and an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor agonist. An intracisternally injected AMPA receptor antagonist alone or in combination with an L-VDCC antagonist sufficiently enhanced scratching. Barbiturate-induced scratching enhancement was observed in another atopic dermatitis model, NC/Nga, but not in histamine-induced acute itch model in normal healthy mice. Overall, our results suggest that a synergistic effect among AMPA receptor inhibition, GABAA receptor activation, and L-VDCC inhibition in the brain mediates barbiturate-induced scratching in atopic dermatitis mice. This observation may provide a novel clue to understanding a supraspinal itch mechanism in chronic diseases such as atopic dermatitis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Barbiturate; Brain; Disease model; Itch; Sleep

Mesh:

Substances:

Year:  2018        PMID: 30125561     DOI: 10.1016/j.ejphar.2018.08.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model.

Authors:  Masanori Fujii; Sayaka Ohgami; Erika Asano; Takanori Nakayama; Takahiro Toda; Takeshi Nabe; Susumu Ohya
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

2.  Study on the Molecular Basis of Huanglian Jiedu Decoction Against Atopic Dermatitis Integrating Chemistry, Biochemistry, and Metabolomics Strategies.

Authors:  Jing Chen; Saizhen Chen; Jinguang Chen; Bixin Shen; Zhengli Jiang; Yubin Xu
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

3.  Living symbiotic bacteria-involved skin dressing to combat indigenous pathogens for microbiome-based biotherapy toward atopic dermatitis.

Authors:  Xinhua Liu; Youteng Qin; Liyun Dong; Ziyi Han; Tianning Liu; Ying Tang; Yun Yu; Jingjie Ye; Juan Tao; Xuan Zeng; Jun Feng; Xian-Zheng Zhang
Journal:  Bioact Mater       Date:  2022-09-12

4.  Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders.

Authors:  Tao Wan; Qi Pan; Yuan Ping
Journal:  Sci Adv       Date:  2021-03-10       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.